Saturday 17 October 2026 Export YARW’s income statement to Excel — free account

Yarrow Bioscience, Inc

Yarrow Bioscience, Inc’s revenue for fiscal 2025 (year ended December 2025) was $570,000.00, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 40.6%, EPS grew 67.1% and free cash flow grew 81.6%, each against the same quarter a year earlier.

18.78 1.22 −6.10%

Follow YARW

Alert me

Market cap: $188.8M
P/E: 0.0×
Fwd P/E: −1.1×
Dividend yield: 0.09%
F-score: 3/9
Altman Z: −31.09
Beneish M: n/a
Dividend safety: 20/100

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 188.75

Revenue 0.48

Net Income (18.71)

Free Cash Flow (16.93)

Net Debt (22.92)

Current Ratio 15.26

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.11)

P/S ratio 33.43

P/B ratio 0.73

Past 5Y EPS Growth —

This Y EPS Growth 7.89%

Next Y EPS Growth 5.84%

Next Y revenue growth 1,092.98%

Next 5Y EPS Growth (29.18%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 49.51%

10-year low 10-year high

P/B against its own 10 years 24.38%

10-year low 10-year high

EV/Sales against its own 10 years 69.53%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 0.02

Annual Dividend Yield 0.09%

	total	individual payouts
2026	0.02	0.01 0.01
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	93	62	29	23
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	96	64	30	24

	2023	2024	2025	Q'26
Payables	2	3	1	1
ST’ Debt	—	—	—	—
Other	2	3	0	0
	8	15	2	2

Compound Annual Growth %

	10y	5y	3y
Sales	2.55%	(51.39%)	6.12%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(0.63%)	(5.83%)	(3.82%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	0	1
’24	0	0	0	0	1
’23	0	0	0	0	0
’22	0	0	0	0	0
’21	0	0	0	0	1
’20	2	12	3	4	21

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(2)	—	—	—
’25	(11)	(11)	(7)	(4)	(33)
’24	(8)	(8)	(9)	(9)	(34)
’23	(5)	(10)	(5)	(5)	(25)
’22	(9)	(8)	(7)	(5)	(29)
’21	(13)	(16)	(18)	(10)	(56)
’20	(52)	(36)	(24)	(25)	(137)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(2)	—	—	—
’25	(11)	(11)	(7)	(4)	(33)
’24	(8)	(8)	(9)	(9)	(34)
’23	(5)	(10)	(5)	(5)	(25)
’22	(9)	(8)	(7)	(5)	(29)
’22	—	—	—	—	(29)
’21	(13)	(16)	(18)	(10)	(56)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(4.00)	(2.14)	—	—	—
’25	(10.00)	(6.50)	(8.50)	(5.64)	(31.50)
’24	(7.50)	(11.00)	(14.50)	(14.00)	(46.50)
’23	(87.00)	(154.50)	(100.50)	(10.00)	(139.00)
’22	71.94	(134.89)	(143.88)	(166.50)	(364.00)
’21	(377.70)	(350.72)	(368.70)	(197.84)	(1.28k)
’20	(3.42k)	(4.35k)	(539.57)	(494.60)	(7.09k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	13,464.00	9,684.00	3,600.00	810.00	99.90	109.10	78.50	14.05	Analyst estimates 2026–2028 Powerpack
	High	—	—	143,496.00	32,511.60	26,928.00	11,880.00	1,062.00	436.50	171.50	215.00
People
People	Employees	32	32	43	40	106	28	12	10	13	10
	Revenue/emp, $m	0.02	0.14	0.08	0.01	0.20	0.03	0.04	0.04	0.04	0.06
Income, $m
Income, $m	Revenue	1	5	4	0	21	1	0	0	1	1
	Gross margin, %	100.00	100.00	100.00	100.00	93.37	100.00	100.00	100.00	100.00	100.00
	EBT	(14)	(29)	(74)	(95)	(256)	(45)	(34)	(28)	(40)	(27)
	EBT margin, %	(2,087.24)	(634.57)	(2,057.05)	(21,524.60)	(1,218.63)	(4,796.56)	(7,113.63)	(6,573.58)	(7,944.71)	(4,689.82)
	Net income	(14)	(29)	(74)	(95)	(256)	(73)	(23)	(28)	(40)	(26)
	Depreciation	0	0	0	0	55	0	0	0	(2)	(1)
Per share, $
Per share, $	Revenue	481.43	3,272.86	499.31	47.13	583.14	16.28	7.49	2.06	0.59	0.67
	Earnings	(10,147.25)	(20,467.63)	(8,525.18)	(11,115.11)	(7,086.33)	(1,276.98)	(364.00)	(139.00)	(46.50)	(31.50)
	Cash flow	(1,617.86)	(20,158.57)	(9,536.67)	(7,807.87)	(3,807.83)	(985.44)	(458.40)	(123.31)	(39.88)	(38.72)
	Capex	(22.14)	(19.29)	(77.36)	(108.30)	(3.14)	0.00	0.00	0.00	(0.14)	0.00
	Free cash flow	(1,640.00)	(20,177.86)	(9,614.03)	(7,916.17)	(3,810.97)	(985.44)	(458.40)	(123.31)	(40.02)	(38.72)
	Book value	21,115.71	37,352.14	18,107.92	1,869.68	1,041.47	850.28	489.83	431.80	61.15	32.46
	Shares, m	0	0	0	0	0	0	0	0	1	1
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	31.58	31.58	16.76	36.13	9.75	56.40	16.47	55.25	284.78	43.52
	P/B	0.00	0.00	0.82	6.37	5.46	1.08	0.25	0.26	2.74	0.89
	EV/Sales	18.59	18.59	(4.62)	23.23	8.54	81.96	91.25	(7.62)	295.03	109.56
	EV/FCF	(3.01)	(3.01)	0.43	(0.97)	(1.31)	(1.35)	(1.48)	0.13	(4.33)	(1.87)
Cash, $m
Cash, $m	Operating cash flow	(2)	(28)	(69)	(73)	(137)	(56)	(29)	(25)	(34)	(33)
	Capex	0	0	(1)	(1)	0	—	—	—	0	—
	Free cash flow	(2)	(28)	(69)	(74)	(137)	(56)	(29)	(25)	(34)	(33)
Balance, $m
Balance, $m	Working capital	28	56	130	47	65	45	29	88	50	28
	Total debt	—	—	—	33	33	0	—	—	—	—
	Net debt	(31)	(60)	(136)	(41)	(26)	(43)	(31)	(93)	(62)	(29)
	Shareholders’ equity	30	52	130	18	37	49	31	89	52	28
Returns, %
Returns, %	ROA	(33.45)	(53.39)	(71.73)	(86.10)	(292.24)	(91.21)	(43.06)	(41.10)	(48.40)	(54.57)
	ROIC	0.00	0.00	0.00	0.00	(1,406.53)	(420.68)	(9,442.46)	0.00	0.00	0.00
	ROE	47.78	67.25	(202.24)	(128.66)	(928.19)	(170.28)	(58.14)	(47.44)	(56.57)	(66.33)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADCT ADC Therapeutics SA	$190.2M	— (loss-making)	— (loss-making)	+2.17% (above 0%: growing)	n/m	+50.98% (above 0%: growing)	87.80%	(132.03%)	Compare
STRO Sutro Biopharma, Inc.	$190.0M	— (loss-making)	— (loss-making)	−84.57% (below 0%: shrinking)	n/m	+14.55% (above 0%: growing)	100.00%	(303.77%)	Compare
YARW Yarrow Bioscience, Inc	$188.8M	— (loss-making)	— (loss-making)	+40.58% (above 0%: growing)	n/m	+81.56% (above 0%: growing)	100.00%	(3,197.94%)
TRDA Entrada Therapeutics, Inc.	$186.1M	— (loss-making)	— (loss-making)	−53.95% (below 0%: shrinking)	n/m	−9.10% (below 0%: shrinking)	100.00%	(5,007.02%)	Compare
UPB Upstream Bio, Inc.	$184.6M	— (loss-making)	— (loss-making)	−17.50% (below 0%: shrinking)	n/m	+9.33% (above 0%: growing)	100.00%	(5,480.98%)	Compare
ELDN Eledon Pharmaceuticals, Inc.	$184.5M	— (loss-making)	—	—	n/m	−28.02% (below 0%: shrinking)	0.00%	0.00%	Compare
SION Sionna Therapeutics, Inc.	$184.5M	— (loss-making)	—	—	n/m	−22.40% (below 0%: shrinking)	—	0.00%	Compare
ACOG Alpha Cognition Inc.	$184.0M	— (loss-making)	—	+267.56% (above 0%: growing)	n/m	−109.25% (below 0%: shrinking)	94.80%	(127.29%)	Compare
BCYC Bicycle Therapeutics PLC Sponsored ADR	$181.4M	— (loss-making)	— (loss-making)	−78.46% (below 0%: shrinking)	n/m	+31.95% (above 0%: growing)	100.00%	(8,673.93%)	Compare
Median of peers	$184.5M	—	—	−35.72%	—	+0.11%	100.00%	(217.90%)

All 614 Biotechnology stocks →

Yarrow Bioscience, Inc (YARW) key facts

Strength: Yarrow Bioscience, Inc’s revenue for fiscal 2025 (year ended December 2025) was $570,000.00, up 13.8% from fiscal 2024.
Yarrow Bioscience, Inc (YARW) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, YARW traded at $18.78, a market capitalization of $188.8 million.
Yarrow Bioscience, Inc pays an annual dividend of $0.02 per share, a yield of 0.09%.
Return on equity was −66.3% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −31.09 (distress zone) for fiscal 2025.